Arthritis Treatment Statistics 2026 | Options, Costs & Key Data

Arthritis is not a single disease — it is an umbrella term covering more than 100 distinct conditions affecting joints, surrounding tissue, and connective tissue throughout the body. In 2026, it remains one of the most prevalent, costly, and disabling chronic conditions in the United States and globally. Up to 27% of US adults — approximately 58.5 million people — have been diagnosed with some form of arthritis, according to the CDC and America’s Health Rankings. Among adults aged 65 and older, the diagnosis rate climbs sharply: ~48% of Americans aged 65 and over had been told by a doctor they have arthritis as of 2024 (CDC/NCHS, Statista February 2026). Globally, ~350 million people have some form of arthritis, and over 20 million people have rheumatoid arthritis specifically (BMC Public Health, 2024). The global rheumatoid arthritis treatment market alone is valued at $32.7 billion in 2026 and is projected to reach $48.2 billion by 2033 — evidence that the treatment economy for this condition is itself a major commercial enterprise.

What makes the 2026 arthritis landscape particularly significant is how dramatically the treatment options have expanded over the past decade. The era of managing arthritis primarily through NSAIDs, corticosteroids, and physical therapy has given way to a far more complex treatment landscape that includes biological disease-modifying antirheumatic drugs (bDMARDs), JAK inhibitors, biosimilars, viscosupplements, regenerative medicine, and FDA-approved precision therapeutics. Biopharmaceuticals are projected to account for 86.9% of the RA treatment market in 2026, driven by biologics’ pivotal role in slowing disease progression and improving quality of life in ways that older drug classes could not. Yet access to these treatments remains deeply unequal: only 26% of Medicare beneficiaries with RA receive a biologic, reflecting cost, prescribing patterns, and coverage barriers that leave the majority of patients on less effective — but far cheaper — treatment protocols.

Interesting Facts: Arthritis Treatment Statistics 2026

ARTHRITIS IN THE US — PREVALENCE SNAPSHOT (2026)
=================================================

  US Adults Diagnosed with Arthritis
  ┌──────────────────────────────────────────────────────┐
  │ All US adults:          ~27%  (~58.5 million)       │
  │ Adults 65+:             ~48%  (CDC/NCHS 2024)       │
  │ With severe joint pain: ~43%  of those diagnosed    │
  └──────────────────────────────────────────────────────┘

  Global RA Treatment Market
  ┌──────────────────────────────────────────────────────┐
  │ 2026 value:  $32.7 billion  ████████████████████     │
  │ 2033 proj.:  $48.2 billion  ████████████████████████ │
  │ CAGR:        5.7% (2026–2033)                        │
  └──────────────────────────────────────────────────────┘

Source: CDC / America’s Health Rankings (2026), CDC/NCHS via Statista (February 2026), Singlecare Arthritis Statistics (April 2026), Persistence Market Research RA Treatment Market (2026), Grand View Research OA Therapeutics Market (2026), BMC Public Health (2024), Lancet Rheumatology (2024)

The prevalence data establishes arthritis as one of the most common chronic conditions in the US, affecting a larger share of the adult population than either diabetes (approximately 11%) or heart disease (approximately 12.5%). The 48% diagnosis rate among Americans aged 65 and over means that nearly one in two older adults is navigating some form of arthritis — a figure that has direct implications for Medicare spending, healthcare infrastructure demand, and the design of elder care systems. The more than 40% of diagnosed adults reporting limitations in usual activities quantifies the functional burden: this is not merely a pain condition but one that materially reduces work capacity, independence, and quality of life for tens of millions of Americans.

The treatment market data reveals a sector defined by the tension between therapeutic innovation and access inequality. The global RA treatment market at $32.7 billion is growing at 5.7% annually — driven by biopharmaceuticals, which account for roughly 86.9% of the market by value. Yet the fact that only 26% of Medicare beneficiaries with RA actually receive a biologic despite their clinical superiority points to a structural gap between what is therapeutically optimal and what is economically accessible. OA therapeutics are growing even faster at an 8.88% CAGR toward $10.89 billion by 2033, driven by aging populations, viscosupplement dominance (48.42% of the OA market), and emerging regenerative therapies. North America alone holds 48.07% of the OA therapeutics market, reflecting the intersection of high prevalence, advanced healthcare infrastructure, and relatively unrestricted access to newer treatment modalities.

Arthritis Treatment Options & Effectiveness 2026

ARTHRITIS TREATMENT SPECTRUM — 2026
=====================================
(From conservative / low-cost to advanced / high-cost)

  Conservative / First-line
  ┌──────────────────────────────────────────────────┐
  │ Physical therapy / exercise     Low cost, proven │
  │ NSAIDs (OTC + prescription)     Low–moderate     │
  │ Topical creams / ointments      Low cost         │
  │ Weight management               Low cost         │
  │ Corticosteroid injections       Moderate         │
  └──────────────────────────────────────────────────┘

  Advanced / Biologic / Surgical
  ┌──────────────────────────────────────────────────┐
  │ DMARDs (e.g., methotrexate)     Moderate         │
  │ Biologics (e.g., adalimumab)    High cost        │
  │ JAK inhibitors                  High cost        │
  │ Viscosupplements (injections)   Moderate         │
  │ Joint replacement surgery       Very high cost   │
  └──────────────────────────────────────────────────┘

Source: America’s Health Rankings (2026), Singlecare Arthritis Statistics (April 2026), Persistence Market Research RA Treatment Market (2026), Grand View Research OA Therapeutics Market (2026), FDA (Breakthrough Therapy Designation 2023), SingleCare/GoodRx cost data

The treatment cost data captures one of healthcare’s most acute access problems. Biologics — the most effective treatments for rheumatoid and psoriatic arthritis — cost between $1,000 and $5,000 per month in brand-name form, placing them out of reach for any patient without comprehensive insurance coverage. Biosimilars have emerged as the critical access solution: as patents expire on blockbuster biologics like Humira (adalimumab) — which was the world’s best-selling drug for many years — biosimilar versions entering the market at 30–60% lower prices are expanding treatment access significantly. The 86.9% biopharmaceutical share of the RA treatment market includes biosimilars, whose adoption is accelerating in 2026 as both payers and patients recognize their clinical equivalence at dramatically lower cost.

For the much larger osteoarthritis population — where biologics are generally not indicated — the viscosupplement segment dominates at 48.42% of the OA therapeutics market, reflecting a treatment model focused on joint lubrication and pain management rather than disease modification. Over 1 million joint replacement surgeries are performed annually in the US — primarily knee and hip replacements for end-stage OA — at a cost of $30,000–$60,000 or more depending on the facility, making them among the most expensive elective procedures in US medicine. The pipeline for osteoarthritis is also shifting in 2026: Resiniferatoxin (RTX), which received FDA Breakthrough Therapy Designation in 2023, represents a genuinely novel non-opioid mechanism for knee OA pain that could reduce both the reliance on corticosteroids and the escalation to surgery if its launch confirms clinical trial efficacy.

Arthritis Demographics, Costs & Workforce Impact 2026

ARTHRITIS BURDEN — US ECONOMIC & DEMOGRAPHIC IMPACT (2026)
===========================================================

  Who Gets Arthritis (US)
  ┌────────────────────────────────────────────────────┐
  │ Women:      60%+ of RA cases (higher than men)     │
  │ Age 65+:    ~48% diagnosed                         │
  │ Black adults: highest RA rates in US               │
  │ Pima/Papago tribes AZ: >5% RA prevalence           │
  └────────────────────────────────────────────────────┘

  Economic Cost (US)
  ┌────────────────────────────────────────────────────┐
  │ Total medical costs associated with arthritis:     │
  │ Among the highest of any chronic condition         │
  │ Work limitations affect millions annually          │
  └────────────────────────────────────────────────────┘

Source: CDC/NCHS via Statista (February 2026), America’s Health Rankings (2026), Singlecare Arthritis Statistics (April 2026), Grand View Research OA Therapeutics Market (2026), Persistence Market Research RA Treatment Market (2026), Osteoarthritis and Cartilage Open (2026), Lancet Rheumatology (2024)

The demographic distribution of arthritis reveals patterns with significant implications for healthcare equity. Women bear a disproportionately higher RA burden — accounting for approximately two-to-three times the RA burden of men — in a condition that is simultaneously more severe and more undertreated in women due to longstanding diagnostic biases in autoimmune disease research. Black Americans have the highest RA rates of any racial group in the US, a disparity that intersects with lower rates of biologic prescription (despite higher clinical need), differences in healthcare access, and the social determinants of health that influence both disease onset and treatment quality. The finding that South Asian older adults experience higher rates of knee OA than other racial groups in the US (2026 Osteoarthritis and Cartilage Open study) adds another dimension to an already complex demographic picture.

The economic burden of arthritis on the US workforce is substantial and often undercounted. With more than 40% of diagnosed adults reporting limitations in usual activities, arthritis is consistently ranked among the leading causes of work disability in the United States. This encompasses both formal disability (inability to work at all) and presenteeism — reduced productivity while present — which studies consistently show is the larger economic cost. The projected 1% annual increase in RA prevalence (CDC, 2025), combined with aging demographics that push the 65+ population (already at 48% arthritis diagnosis rates) to a larger share of the total population, means that arthritis-related healthcare costs and workforce impacts are structurally set to increase regardless of treatment advances. The race between improved therapeutics (biologics, biosimilars, emerging nonopioid treatments) and rising prevalence will define the arthritis treatment landscape through the 2030s.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE